Document is current
Any future updates will be listed below
-
Authors
Tsiogka, Aikaterini https://orcid.org/0000-0002-6853-9788
Soulaidopoulos, Stergios
Gregoriou, Stamatios
Rompoti, Natalia
Panagakis, Pantelis
Papoutsaki, Marina
Kostakis, Panagiotis
Kontochristopoulos, George
Tsioufis, Konstantinos
Vlachopoulos, Charalambos
Stratigos, Alexander
Rigopoulos, Dimitrios
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct07169682 at ClinicalTrials.govDocuments that mention this clinical trial
Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study
https://doi.org/10.1007/s13555-025-01549-1
- License Information
-
More Information
Article History
Received: 10 July 2025
Accepted: 15 September 2025
First Online: 8 October 2025
Declarations
:
: Stamatios Gregoriou is an Editorial Board member of Dermatology and Therapy. Stamatios Gregoriou was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Aikaterini Tsiogka, Stergios Soulaidopoulos, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos and Dimitrios Rigopoulos declare no conflict of interest.
: The study was approved by the Andreas Syggros Hospital’s ethics committee (AP 3610/20-05-2021). The study was performed in accordance with the Helsinki Declaration of 1964, all subjects provided informed consent to participate in the study and for publication of their data. A retrospective study registration at Clinicaltrials.gov was performed to pursue publication of valuable research.
